Journal of experimental zoology. Part A, Ecological and integrative physiology
July 1, 2025
Charlys Rhands Coelho de Moura, Hermínio José da Rocha Neto, Regina Lucia Dos Santos Silva et al.
Agoutis is a medium-sized wild rodent with potential for use as an experimental model. This study aimed to evaluate physiological parameters of arrhythmogenesis in this species, by HR-ECG and VCG techniques, under physical and pharmacological containment (ketamine-xylazine and butorphanol). Eight agouti in which the physiological parameters of arrhythmogenesis were evaluated by HR-ECG and VCG...
Experimental Neurology
July 1, 2025
Mengqin Shan, Chaoyang Tong, Xin Fu et al.
2 citations
Growing evidence suggests that prolonged or repeated exposure to general anesthesia is associated with white matter alteration in children, which may underlie subsequent cognitive and behavioral abnormalities. Numerous infants undergo anesthesia for surgery each year, so it is imperative to identify the risk factors and find preventative treatment to prevent the effects of early anesthesia...
Psychiatry Research
July 1, 2025
Hiroe Hu, Alaina N Tillman, Miyu Fujita et al.
2 citations
Subanesthetic-dose ketamine has recently been reported to improve hedonic pleasures associated with social interactions and altruism in individuals with treatment-resistant depression. However, whether ketamine-among other glutamate receptor modulators-also improves empathy and/or prosocial behavior in humans remains unknown. Under a framework grounded in neurobiology that proposes that...
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
July 1, 2025
Altamura Mario, Leccisotti Ivana, Moretti Maria Claudia et al.
5 citations
Treatment-resistant depression (TRD) presents substantial clinical challenges, particularly in patients with Alzheimer's disease (AD) and older adults experiencing late-life depression. Traditional monoaminergic therapies often fail in this population due to neurodegenerative changes that impact receptor dynamics and neurotransmitter systems. Emerging evidence suggests that N-methyl-D-aspartate...
Psychiatry Research Neuroimaging
July 1, 2025
Anna Monn, Corinne Eicher, Annia Rüesch et al.
2 citations
Treatment-resistant depression (TRD) is associated with reduced quality of life and elevated mortality, posing a major challenge to psychiatric care. After non-response to conventional treatments, next-level interventions such as (es)ketamine are recommended, though remission rates remain variable. Identifying reliable markers of treatment response is therefore critical. Recent evidence...
Biological Psychiatry Global Open Science
July 1, 2025
Stephen A Murata, Zachary B Madaj, Colt D Capan et al.
1 citation
Treatment-resistant depression (TRD) remains a challenge, but intravenous racemic ketamine offers rapid antidepressant effects. Reliable biomarkers are needed. In this study, we examined kynurenine pathway metabolites and inflammatory cytokines as predictors of ketamine response. The Bio-K study was a multicenter, open-label trial of 74 patients with TRD who received 3 ketamine infusions over...
June 30, 2025
NMDA antagonists like amantadine and memantine are considered third-line treatments for catatonia after benzodiazepines and ECT. NMDA antagonists can be used as monotherapy for catatonia but are most commonly employed as augmentation to benzodiazepines. Despite a 91% response rate in some cases, ketamine is not recommended for catatonia due to its unpredictability and potential to worsen symptoms.
June 30, 2025
Scott R. Beach
NMDA-antagonisten zoals amantadine en memantine worden beschouwd als derdelijnsbehandelingen voor katatonie, na benzodiazepinen en ECT. NMDA-antagonisten kunnen als monotherapie worden ingezet bij katatonie, maar worden het meest gebruikt als augmentatie van benzodiazepinen. Ondanks een responspercentage van 91% in sommige gevallen, wordt ketamine niet aanbevolen bij katatonie vanwege de...
Journal of Psychopharmacology
June 30, 2025
Jess Kerr-Gaffney, Anna Tröger, Alice Caulfield et al.
6 citations
Ketamine has emerged as a putative rapid-acting treatment option for psychiatric disorders, particularly treatment-resistant depression. Chronic recreational ketamine use is associated with ketamine-induced urological toxicity, raising concerns over the safety of repeated ketamine treatments. This systematic review aimed to synthesise urological findings from clinical trials and observational...
CNS Spectrums
June 30, 2025
Jose-Manuel Quintero, Rosa-Helena Bustos, Sharon Lechtig-Wassermann et al.
6 citations
Ketamine, originally synthesized in 1962, has gained increasing attention due to its rapid and sustained antidepressant effects in treatment-resistant depression (TRD). Unlike traditional antidepressants, ketamine acts on multiple neurotransmitter systems, including NMDA receptor antagonism and AMPA receptor potentiation, offering a novel mechanism for mood regulation. Beyond psychiatry,...